Periodic Reporting for period 2 - ABwipe (COVID-19 pandemic: An innovative, safe and effective bio-decontamination technology for non-toxic removal of biological agents, including coronavirus)
Periodo di rendicontazione: 2021-08-01 al 2023-01-31
Aquila Bioscience Ltd. (ABL) is a Biomedical Research & Development SME which has developed an innovative Pathogen Capture Technology (PCT) that uses natural biomolecules to safely capture and remove pathogens.
ABL has developed a unique pilot product, the ABD Device, a cellulose based decontamination wipe that incorporates natural binders that can capture and remove all pathogens including viruses, bacteria, fungi and their mutants in a safe and effective manner. The technology consists of non-toxic chemicals that can be safely used on sensitive skin surfaces such as face, around the eyes, nose and mouth and mucosal surfaces to disinfect these ports of entry from pathogens.
Work Objectives:
• To develop the ABwipe, now referred to as the ABD Device, from a laboratory prototype to a commercial large-scale manufacturing environment.
• To obtain external verification of the efficacy of the technology from independent laboratories.
• To gain potential customer insights through pilot studies.
ABL has developed a unique pilot product, the ABD Device, a cellulose based decontamination wipe that incorporates natural binders that can capture and remove all pathogens including viruses, bacteria, fungi and their mutants in a safe and effective manner. The technology consists of non-toxic chemicals that can be safely used on sensitive skin surfaces such as face, around the eyes, nose and mouth and mucosal surfaces to disinfect these ports of entry from pathogens.
Work Objectives:
• To develop the ABwipe, now referred to as the ABD Device, from a laboratory prototype to a commercial large-scale manufacturing environment.
• To obtain external verification of the efficacy of the technology from independent laboratories.
• To gain potential customer insights through pilot studies.
Lab-scale prototypes of the ABD Devices were developed and transferred successfully to an in-house manufacturing process and pilot batches of >2,000+ units have been achieved.
Pilot studies have been carried out with potential customers and the ABD Device has been well received during these review and feedback sessions.
An external laboratory, NeoVirTech, demonstrated the ability of the device to effectively capture and remove between 99.9-99.99% of SARS-CoV-2 from human skin explants.
The product has been developed to be eco-friendly as it is largely made up of biodegradeable material and environmentally safe formulation ingredients.
Despite the travel restrictions of the Covid-19 pandemic, ABL and the ABD Device have been represented at a number of national and international conferences and media articles.
Pilot studies have been carried out with potential customers and the ABD Device has been well received during these review and feedback sessions.
An external laboratory, NeoVirTech, demonstrated the ability of the device to effectively capture and remove between 99.9-99.99% of SARS-CoV-2 from human skin explants.
The product has been developed to be eco-friendly as it is largely made up of biodegradeable material and environmentally safe formulation ingredients.
Despite the travel restrictions of the Covid-19 pandemic, ABL and the ABD Device have been represented at a number of national and international conferences and media articles.
Currently, all disinfection and decontamination products are based on biocides and other toxic chemicals that have harmful effects on human skin, health and the environment. The ABD Device has the potential to change this reliance on toxic chemicals and alcohol based wipes worldwide. These developments, including the proven capture of SARS-CoV-2 from human skin, are being successfully translated into new technologies that can give a competitive advantage to EU industry, save and improve the lives of its citizens and also protect the environment.